1. Home
  2. SCLX vs FGB Comparison

SCLX vs FGB Comparison

Compare SCLX & FGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • FGB
  • Stock Information
  • Founded
  • SCLX 2011
  • FGB 2007
  • Country
  • SCLX United States
  • FGB United States
  • Employees
  • SCLX N/A
  • FGB N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • FGB Finance/Investors Services
  • Sector
  • SCLX Health Care
  • FGB Finance
  • Exchange
  • SCLX Nasdaq
  • FGB Nasdaq
  • Market Cap
  • SCLX 72.5M
  • FGB 61.9M
  • IPO Year
  • SCLX N/A
  • FGB N/A
  • Fundamental
  • Price
  • SCLX $0.45
  • FGB $4.38
  • Analyst Decision
  • SCLX Strong Buy
  • FGB
  • Analyst Count
  • SCLX 3
  • FGB 0
  • Target Price
  • SCLX $11.33
  • FGB N/A
  • AVG Volume (30 Days)
  • SCLX 184.3K
  • FGB 53.0K
  • Earning Date
  • SCLX 03-11-2025
  • FGB 01-01-0001
  • Dividend Yield
  • SCLX N/A
  • FGB 8.92%
  • EPS Growth
  • SCLX N/A
  • FGB N/A
  • EPS
  • SCLX N/A
  • FGB N/A
  • Revenue
  • SCLX $55,152,000.00
  • FGB N/A
  • Revenue This Year
  • SCLX $32.77
  • FGB N/A
  • Revenue Next Year
  • SCLX $50.71
  • FGB N/A
  • P/E Ratio
  • SCLX N/A
  • FGB N/A
  • Revenue Growth
  • SCLX 9.41
  • FGB N/A
  • 52 Week Low
  • SCLX $0.38
  • FGB $2.85
  • 52 Week High
  • SCLX $2.63
  • FGB $3.74
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 42.08
  • FGB 60.01
  • Support Level
  • SCLX $0.40
  • FGB $4.25
  • Resistance Level
  • SCLX $0.53
  • FGB $4.32
  • Average True Range (ATR)
  • SCLX 0.05
  • FGB 0.10
  • MACD
  • SCLX 0.01
  • FGB 0.01
  • Stochastic Oscillator
  • SCLX 47.59
  • FGB 66.13

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About FGB First Trust Specialty Finance and Financial Opportunities Fund

First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.

Share on Social Networks: